As seen for RGMA and RGMB, predicted mutations of RGMC/HJV are found in many different cancers, with transcripts encoding mutant proteins being detected in 25% of prostate cancers, 10% of ovarian carcinomas, and 8.4% of melanomas (see Results). This evidence concerns the gene HJV and prostate cancer.